Form 4: Director Yasunori Kaneko Increases Stake in Arcus

Director Yasunori Kaneko acquired 5,700 restricted stock units and 16,900 stock options in Arcus Biosciences, Inc.

Summary

• Director Yasunori Kaneko was granted 5,700 restricted stock units (RSUs) on June 11, 2026.
• The director also received a grant of 16,900 stock options with an exercise price of $23.30.
• Both the RSUs and stock options are scheduled to vest on the earlier of June 11, 2027, or the next annual meeting of stockholders.
• The reporting person maintains significant indirect holdings through Kaneko Investments, LLC (252,524 shares), Kaneko Capital, LLC (505,050 shares), and a trust (174,681 shares).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Director alignment with shareholder interests is reinforced through additional equity-based compensation.
• The reporting person maintains a substantial long-term ownership position in the company.

Negatives

• The issuance of additional equity and options results in minor dilution to existing shareholders.

Risks

• Vesting of equity is subject to the company's continued operation and potential change-in-control scenarios.
• Stock options are currently priced at $23.30, which may be out-of-the-money depending on future market performance.

Future Outlook

The equity grants are standard compensation for board service, with vesting tied to the 2027 annual meeting or one year from the grant date.

Industry Context

StockSavvy.ai notes that director equity grants are standard practice in the biotechnology sector to ensure board members remain incentivized toward long-term value creation.

Comparison to Industry Standards

• The grant structure is consistent with standard corporate governance practices for mid-cap biotechnology firms.
• The use of both RSUs and options is a common retention tool for board members in the life sciences industry.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity instruments.

Next Steps

• Vesting of RSUs and options on June 11, 2027.

Key Dates

Keywords

Arcus Biosciences, RCUS, Form 4, Insider Trading, Equity Compensation, Director Ownership